A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Protagonist Therapeutics, Inc
PTGX
$8.6B
Mkt Cap
$136.11
+0.50%
Protagonist Therapeutics, Inc (PTGX) has a 5-year average return on invested capital (ROIC) of -10.3%. This is below average and may indicate limited pricing power.
Protagonist Therapeutics, Inc (PTGX) has a market capitalization of $8.6B. It is classified as a mid-cap stock.
Protagonist Therapeutics, Inc (PTGX) does not currently pay a regular dividend.
Protagonist Therapeutics, Inc (PTGX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Protagonist Therapeutics, Inc (PTGX) generated $56 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Protagonist Therapeutics, Inc (PTGX) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Protagonist Therapeutics, Inc (PTGX) reported earnings per share (EPS) of $-2.05 in its most recent fiscal year.
Protagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and development company with a validated technology platform. Our programs fall into three broad therapeutic areas: (i) inflammation and immunology (“I&I”), (ii) hematology and (iii) metabolic diseases. Our aim is to develop medicines for biologically and commercially validated targets which demonstrate a strong differentiation compared to existing therapies. Our Development Products and Discovery Programs Icotyde™ (icotrokinra) Icotyde™ (icotrokinra) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which underpins the inflammatory response in psoriasis and offers potential in other IL-23-mediated diseases. Icotyde is licensed to Janssen Biotech, Inc., a Johnson & Johnson company (“JNJ”), under a license and collaboration agreement initially entered into in 2017.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 434M | 60M | - | - |
| Net Income | -130M | -130M | 275M | -79M | -127M | -126M |
| EPS | $-2.05 | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 |
| Free Cash Flow | 56M | 56M | 183M | -71M | -109M | -109M |
| ROIC | -25.2% | -20.2% | 93.2% | -23.5% | -59.1% | -41.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.00 | 0.02 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -158M | -158M | 253M | -94M | -131M | -126M |
| Operating Margin | 0.0% | - | 58.2% | -156.1% | - | - |
| ROE | -21.2% | -20.2% | 40.8% | -23.5% | -59.1% | -41.8% |
| Shares Outstanding | 63M | 63M | 65M | 57M | 49M | 46M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 20M | 31M | N/A | N/A | N/A | N/A | 60M | 434M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 46M | 59M | 65M | 75M | 126M | 126M | 120M | 138M | 159M | 159M |
| SG&A | 12M | 14M | 16M | 19M | 27M | 32M | 33M | 43M | 45M | 45M |
| EBIT | -38M | -42M | -81M | -65M | -126M | -131M | -94M | 253M | -158M | -158M |
| Op. Margin | -188.9% | -136.7% | N/A | N/A | N/A | N/A | -156.1% | 58.2% | N/A | 0.0% |
| Net Income | -37M | -39M | -77M | -66M | -126M | -127M | -79M | 275M | -130M | -130M |
| Net Margin | -184.2% | -125.9% | N/A | N/A | N/A | N/A | -131.6% | 63.3% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 300K | 300K | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | -30.6% | -34.6% | -86.0% | -22.9% | -41.8% | -59.1% | -23.5% | 93.2% | -20.2% | -25.2% |
| ROE | -30.6% | -34.6% | -96.5% | -23.7% | -41.8% | -59.1% | -23.5% | 40.8% | -20.2% | -21.2% |
| ROA | -22.6% | -27.9% | -49.8% | -20.4% | -36.1% | -51.4% | -22.1% | 37.0% | -18.4% | -19.5% |
| Cash Flow | ||||||||||
| Op. Cash Flow | 3.9M | -50M | -42M | -72M | -108M | -108M | -70M | 184M | 58M | 58M |
| Free Cash Flow | 3.2M | -50M | -42M | -73M | -109M | -109M | -71M | 183M | 56M | 56M |
| Owner Earnings | -775K | -57M | -51M | -81M | -125M | -133M | -101M | 146M | 10M | 10M |
| CapEx | 666K | 486K | 967K | 471K | 1.1M | 795K | 609K | 1.4M | 1.6M | 1.6M |
| Maint. CapEx | 406K | 527K | 703K | 948K | 813K | 1.0M | 977K | 826K | 1.3M | 1.3M |
| Growth CapEx | 260K | 0 | 264K | 0 | 288K | 0 | 0 | 529K | 310K | 310K |
| D&A | 406K | 527K | 703K | 948K | 813K | 1.0M | 977K | 826K | 1.3M | 1.3M |
| CapEx/OCF | 17.2% | N/A | N/A | N/A | N/A | N/A | N/A | 0.7% | 2.8% | 2.8% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.2M | 6.9M | 8.4M | 7.9M | 16M | 24M | 29M | 38M | 46M | 46M |
| Debt Repayment | 0 | 0 | 0 | 11M | 11M | 11M | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | N/A | N/A | -116M | -290M | -321M | -234M | -340M | -408M | -557M | -118M |
| Cash & Equiv. | 106M | 82M | 33M | 117M | 124M | 126M | 187M | 97M | 128M | 128M |
| Long-Term Debt | N/A | N/A | 9.8M | 9.8M | 0 | N/A | N/A | N/A | N/A | 10M |
| Debt/Equity | 0.36 | 0.24 | 0.21 | 0.06 | 0.02 | 0.02 | 0.00 | 0.02 | 0.02 | 0.02 |
| Interest Coverage | N/A | N/A | -476.5 | -107.9 | -210.4 | -219.7 | N/A | N/A | N/A | N/A |
| Equity | 121M | 113M | 80M | 280M | 300M | 216M | 337M | 675M | 615M | 615M |
| Total Assets | 164M | 139M | 155M | 324M | 348M | 248M | 358M | 745M | 668M | 668M |
| Total Liabilities | 43M | 27M | 75M | 45M | 48M | 32M | 21M | 69M | 53M | 53M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -102M | -140M | -218M | -284M | -409M | -537M | -616M | -341M | -471M | -471M |
| Working Capital | 108M | 111M | 110M | 275M | 297M | 212M | 334M | 544M | 532M | 532M |
| Current Assets | 151M | 138M | 145M | 316M | 341M | 243M | 356M | 592M | 578M | 578M |
| Current Liabilities | 43M | 26M | 35M | 40M | 44M | 31M | 21M | 47M | 45M | 45M |
| Per Share Data | ||||||||||
| EPS | -2.09 | -1.74 | -2.98 | -1.92 | -2.71 | -2.60 | -1.39 | 4.23 | -2.05 | -2.05 |
| Owner EPS | -0.04 | -2.57 | -1.95 | -2.36 | -2.70 | -2.72 | -1.77 | 2.24 | 0.16 | 0.16 |
| Book Value | 6.82 | 5.03 | 3.09 | 8.12 | 6.48 | 4.40 | 5.93 | 10.38 | 9.68 | 9.68 |
| Cash Flow/Share | 0.22 | -2.23 | -1.60 | -2.10 | -2.33 | -2.21 | -1.24 | 2.83 | 0.91 | -2.03 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 17.7M | 22.4M | 25.9M | 34.5M | 46.3M | 49.0M | 56.8M | 65.1M | 63.5M | 63.5M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 9.2 | N/A | -66.4 |
| P/FCF | 112.7 | N/A | N/A | N/A | N/A | N/A | N/A | 13.9 | 100.5 | 154.1 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 8.4 | N/A | N/A |
| Price/Book | 3.0 | 1.3 | 2.3 | 2.8 | 5.3 | 2.3 | 3.9 | 3.8 | 9.2 | 14.1 |
| Price/Sales | 12.9 | 7.8 | N/A | N/A | N/A | N/A | 18.5 | 5.3 | N/A | N/A |
| FCF Yield | 0.9% | -35.4% | -23.4% | -9.2% | -6.9% | -21.5% | -5.4% | 7.2% | 1.0% | 0.6% |
| Market Cap | 361M | 142M | 181M | 794M | 1.6B | 506M | 1.3B | 2.5B | 5.6B | 8.6B |
| Avg. Price | 14.66 | 10.78 | 10.62 | 15.02 | 33.03 | 14.82 | 19.55 | 35.17 | 56.95 | 136.11 |
| Year-End Price | 20.43 | 6.36 | 7.00 | 23.05 | 34.01 | 10.33 | 23.13 | 38.96 | 88.78 | 136.11 |
Protagonist Therapeutics, Inc passes 0 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 154.9x vs a median of 13.9x. At current prices, the estimated annualized return to fair value is +46.2%.
Protagonist Therapeutics, Inc (PTGX) has a return on equity (ROE) of -20.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 9 years of financial data for Protagonist Therapeutics, Inc (PTGX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Protagonist Therapeutics, Inc (PTGX) has a book value per share of $9.68, based on its most recent annual SEC filing.